Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chipotle Mexican Grill, Inc. (CMG) vs Cytokinetics Inc (CYTK) Price & Performance

Chipotle Mexican Grill, Inc.Trade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Chipotle Mexican Grill, Inc. vs Cytokinetics Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.65 (market cap $40.49B), while Cytokinetics Inc trades at $76.6 (market cap $10.63B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 3.8× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.

CMGCYTK
Market Cap
$40.49B$10.63B
Sector
Consumer CyclicalTechnology
52-Week High
$44.04$87.26
52-Week Low
$28.17$34.31
Enterprise Value
$45.24B$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill (CMG) trades at $32.25, up 0.34% on the day, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds from a recent salmonella outbreak linked to jalapeños, contributing to a 12.64% weekly drop. Fundamentally, revenue growth remains robust, reaching $11.93B in 2025, with strong profitability metrics including a 49.56% ROE. Analyst consensus is overwhelmingly bullish with a $42.17 price target, though technical indicators show selling pressure with key support at $32.

The outlook for CMG balances strong fundamentals against near-term operational risks. Wall Street's buy ratings (70.15%) reflect confidence in long-term growth, but recent food safety issues and declining net income margins pose immediate challenges. Investors should weigh the company's consistent revenue trajectory against potential volatility from ongoing outbreaks and rising costs.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.

Read more on CMG

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK